NASDAQ: $CRBP Promising Developments in Obesity Treatment The landscape of weight management is evolving rapidly, and a recent announcement from Corbus Pharmaceuticals has caught the attention of the medical community. The company has officially released positive topline data from their CANYON-1 study, which evaluated their daily oral candidate, CRB-913. Understanding the CANYON-1 Study The CANYON-1…